Cancer-associated thrombosis: limitations of conventional models and advances with endothelial cell-based microfluidics incorporating thrombin generation

Apart from cancer progression itself, cancer-associated thrombosis (CAT) is the second leading cause of death among cancer patients. However, the mechanisms underlying CAT remain incompletely understood. Traditional animal models cannot fully reproduce the complex pathophysiological process of CAT in humans. Meanwhile, existing clinical prediction models are still insufficient to provide reliable risk prediction tools for venous thromboembolism (VTE) in cancer patients. With the accelerating development of microfluidics technology, it has become possible to construct thrombotic microenvironments with high physiological relevance in vitro, providing a new platform for the study of CAT. In this review, we summarized the contributions and limitations of animal models and clinical studies to CAT, and highlighted a series of artificial vascular microfluidics developed by our research group in recent years that can, to some extent, simulate the in vivo microenvironment for CAT. Based on this microfluidics platform, we conducted thrombin generation analysis to explore the potential mechanisms of cancer-related thrombosis and predict VTE risk in cancer patients. Finally, we further discuss the key issues and the challenges in the future.